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What is already known about this topic? 
• Emerging evidence supports an association between more common 
inflammatory skin diseases and chronic kidney disease (CKD), but the size 
and nature of this association remain unclear.   
What does this study add? 
• People with CKD were more likely to have atopic eczema (14%), psoriasis 
(13%) and hidradenitis suppurativa (49%), compared to those without CKD.  
• The link between inflammatory skin diseases and CKD did not appear to be 
mediated through cardiovascular co-morbidity, hypertension or nephrotoxic 
drugs.  
• A stronger association with CKD among those with severe atopic eczema and 
psoriasis was consistent with a dose-response association (between 
increasingly severe eczema/psoriasis and increasing CKD).  
• There was no evidence of CKD incidence being associated with atopic eczema 
or psoriasis in the cohort of people with diabetes. 
 
 




Background: Emerging evidence suggests an association between common 
inflammatory skin diseases and chronic kidney disease (CKD).  
Objective: To explore the association between CKD stages 3-5 and atopic eczema, 
psoriasis, rosacea, and hidradenitis suppurativa. 
Methods: We undertook two complementary analyses; a prevalent case-control and a 
cohort study using routinely collected primary care data (UK Clinical Practice 
Research Datalink [CPRD]).  
We matched individuals with CKD3-5 in CPRD on March 2018 with up to five 
individuals without CKD on GP practice, age and sex. We compared the prevalence 
of CKD3-5 among individuals with and without each inflammatory skin disease.  
We included individuals in CPRD with diabetes mellitus (2004-2018) in a cohort 
analysis to compare the incidence of CKD3-5 among people with and without atopic 
eczema and psoriasis. 
Results: There were 56,602 cases with CKD3-5 and 268,305 controls without. Cases 
were more likely than controls to have a history of atopic eczema (odds ratio [OR] 
1.14; 99% confidence interval 1.11-1.17), psoriasis (1.13; 1.08-1.19), or hidradenitis 
suppuritiva (1.49; 1.19-1.85), but were slightly less likely to have been diagnosed 
with rosacea (0.91; 0.86-0.95), after adjusting for age, sex, practice (matching 
factors), index of multiple deprivation, diabetes, smoking, harmful alcohol use and 
obesity. Results remained similar after adjusting for hypertension and cardiovascular 
disease. In the cohort with diabetes (N=335,827), there was no evidence that CKD3-5 
incidence was associated with atopic eczema or psoriasis. 
Conclusions: Atopic eczema, psoriasis, and hidradenitis suppurativa are weakly 
associated with CKD3-5. Future research is needed to elucidate potential mechanisms 











Chronic kidney disease (CKD) affects up to 13% of the world’s population,1 
and is associated with death and progression to end-stage renal disease.2–5 Established 
risk factors for CKD include older age, diabetes, and hypertension, but for most cases, 
the aetiology of CKD remains unknown.6,7  
Skin diseases are a leading cause of disability worldwide,8 and inflammatory 
skin diseases are associated with a range of co-morbidities.9,10 Emerging evidence 
supports an association between many inflammatory skin diseases and CKD. 
Longitudinal studies demonstrate increased CKD incidence in people with 
psoriasis;11–14 and cross-sectional evidence supports associations between reduced 
kidney function or renal abnormalities, and hidradenitis suppurativa, rosacea and 
atopic eczema.15–17. Inflammatory skin diseases may be associated with CKD through 
increased metabolic syndrome risk and cardiovascular disease in people with skin 
conditions;9,18,19 the use of nephrotoxic medications to manage skin diseases (or 
associated conditions);20 or chronic low-grade inflammation of skin disease.21,22 
Exploring the association between inflammatory skin conditions and CKD 
could help identify at-risk populations who may benefit from regular renal function 
monitoring. It could also guide prudent systemic nephrotoxic prescribing for people 
with inflammatory skin conditions, and provide insight into pathologic mechanisms 
leading to CKD. Elucidating the nature of an association between inflammatory skin 
diseases and CKD could guide targeted investigations into the possible role of skin 
conditions as CKD risk factors. We, therefore, aimed to compare the prevalence of 
specific common skin diseases (i.e. atopic eczema, psoriasis, rosacea, and hidradenitis 
suppurativa) in adults with and without CKD, and assess whether atopic eczema and 
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CKD diagnosis relies on blood and urine tests, which are not recommended as routine 
screening in the general population.23,24. It is, therefore, difficult to establish the onset 
of CKD in routinely-collected data.24 However, prevalent CKD stages 3-5 (CKD3-5) 
based on blood tests only can be reliably detected in the general population;25 and new 
CKD3-5 cases can be captured among specific at-risk populations (e.g. people with 
diabetes), who are more likely to undergo guideline-recommended routine renal 
function testing.24 We conducted two complementary matched analyses (1. a 
population-based prevalent matched case-control study in those with and without 
CKD3-5; and 2. a cohort study restricted to people with diabetes mellitus) using 
routinely-collected primary care electronic health record data from the United 
Kingdom Clinical Practice Research Datalink (UK CPRD Gold). We were able to 
include, through the case-control, a large population-based sample of UK primary 
care (powered to detect small associations). The complementary cohort analysis 
offered a view of a smaller specific sub-population (i.e. those with diabetes) where the 
timing of CKD could be more reliably ascertained. The CPRD includes primary care 
data, including demographic information, coded diagnoses (Read codes), prescriptions 
and secondary care referrals.26,27 Analyses of gaps in data entry and recorded deaths in 
each practice assure the data quality (i.e. ‘up-to-standard’ status), and diagnoses 
recorded in CPRD have been extensively validated.27–29. The CPRD  is nationally-
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representative, covering approximately 7% of the UK population.27Study design and 
population 
Case-control study  
All people aged 25 years or older, alive and registered in an up-to-standard 
CPRD practice for at least one year on 31/03/2018 were eligible for inclusion. We 
used a validated algorithm to ascertain current CKD status and restricted to 
individuals aged 25 years or older, as CKD3-5 below 25 is rare.25,30 We matched each 
individual with CKD3-5 (cases) with up to five individuals without CKD3-5 
(controls), on age (i.e. same year of birth), sex, and general practice. We compared the 
proportion of people with an inflammatory skin disease (diagnosed before 
31/03/2018) among CKD3-5 cases and controls, repeating the analysis separately for 
each inflammatory skin condition (i.e. atopic eczema, psoriasis, rosacea and 
hidradenitis, see “Outcomes” and “Exposures” sections). See Figure S1 for a 
graphic representation of the study designs. 
Cohort study  
All adults with diabetes mellitus in CPRD, aged 25 years or older (01/04/2004 
to 31/03/2018) were eligible for inclusion. Follow up began at the latest of: a) one 
year after practice registration (to allow time for GPs to record previous medical 
history, for robust capture of baseline characteristics and so that we could be more 
confident that we had captured new-onset CKD3-5); b) the date that the general 
practice reached CPRD quality standards; c) start of the study (01/04/2004); or d) the 
date of their first record of a diabetes diagnosis. We excluded those with pre-existing 
CKD3-5 (see Outcomes section) and compared new CKD3-5 incidence among 
people with and without psoriasis or atopic dermatitis (i.e. the more common of the 
explored skin conditions) at cohort entry. We followed each participant until incident 
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CKD3-5 (outcome), or the earliest of: a) date of death; b) change of practice; c) last 
data collection from practice; or d) end of the study (31/03/2018). (Appendix S2 for 
diabetes definition) 
Outcomes 
We defined the primary outcome, CKD3-5, as being on renal replacement 
therapy, having received a renal transplant, or having two measurements of estimated 
glomerular filtration rate (eGFR) <60 mL/min/1.73m2 calculated from serum 
creatinine test results (using the Chronic Kidney Disease Epidemiology Collaboration 
[CKD-EPI] equation) recorded in primary care at least three months apart.31 The 
CKD-EPI equation accounts for black ethnicity when estimating glomerular filtration 
rate,32 as only 3.7% of the CPRD population is black, we classified individuals with 
no record of ethnicity as white.25 Various methods are used in the UK to measure 
serum creatinine, but most laboratories did not report standardised values up to at 
least 2013.33 Following the approach taken in previous CPRD studies,34–36 we 
multiplied the recorded values of creatinine by 0.95 to correct for lack of isotope-
dilution mass spectrometry standardisation.37  
For the case-control analysis, we identified all serum creatinine test results 
recorded in primary care over a five-year period (01/04/2013 to 31/03/2018). Using 
the same approach as a previous validation study, we considered those who did not 
meet the CKD3-5 criteria during that time-period as not having CKD3-5.25 In the 
cohort analysis, we used the latest of the two creatinine measurements (recorded at 
least three months apart) required to fulfil the diagnostic criteria as the date of 
incident CKD3-5. Our secondary outcome was CKD stage based on the eGFR 
recorded on date of incident CKD diagnosis (by eGFR: Stage 3a [45-59 
mL/min/1.73m2]; 3b [30-44 mL/min/1.73m2]; stage 4/5 [<30 mL/min/1.73m2]; renal 
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replacement therapy).25,38 We excluded from the cohort analysis those with at least 
one low eGFR<60 ml/min/1.73m2 or a diagnostic code compatible with RRT before 
cohort entry. 
Exposures 
We used definitions of atopic eczema (positive predictive value [PPV] 86%), 
psoriasis (PPV=90%), hidradenitis suppurativa, and rosacea that have previously been 
applied in CPRD.39–42 Diagnoses were based on the presence of recorded diagnostic 
codes (as well as therapies for atopic eczema). A previous validation study assured the 
exclusion of non-atopic eczema cases). We chose these specific inflammatory skin 
diseases as exposures since they are common and predominantly managed in primary 
care (further details in Appendix S3).41,43,44  
Covariate selection 
We used a directed acyclic graph to guide a-priori informed selection of 
covariates and avoid collider bias.45,46 We, consequently, considered the following 
covariates: age (categorised into five-year intervals in the cohort study); sex; GP 
practice; level of deprivation (using quintiles of the 2015 Index of Multiple 
Deprivation [IMD]); ethnicity (White/South Asian/Black/Other/Mixed); smoking 
status [current/ex/never]; alcohol use; body mass index (BMI) (<18.5, 20.0-24.0, 
25.0-29.0, >30.0 kg/m2); diabetes; cardiovascular disease (i.e. ischemic heart disease, 
chronic heart failure and peripheral arterial disease); hypertension; medications used 
to treat skin conditions with known renal implications (ciclosporin [nephrotoxic 
requiring monitoring], methotrexate [contraindicated for advanced CKD], 
mycophenolate mofetil [associated with anaemia and infection risk but not strictly 
contraindicated]). All morbidity code lists used in this study are available to download 
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(https://doi.org/10.17037/DATA.00001205), and additional details are available in 
Appendix S4.  
Statistical analysis 
Case-control study  
We initially described the characteristics of those with and without CKD3-5. We then 
used conditional logistic regression to estimate the odds ratios comparing odds of 
CKD3-5 in individuals with each skin condition separately (main analysis) compared 
to those without. All analyses implicitly accounted for matching factors (age, sex, GP 
practice). We fitted the following sequential regression models: a) a minimally-
adjusted model, additionally including IMD; b) a fully-adjusted model, additionally 
including diabetes mellitus, smoking, harmful alcohol use and obesity; c) a final 
model also included potential mediators: hypertension and cardiovascular disease. We 
used complete case analysis.47 To preserve matching, we excluded entire matched sets 
if a person with CKD3-5 was excluded (e.g. due to missing data or restrictions in a 
sensitivity analysis), or if no individuals without CKD3-5 remained in the set.  
We conducted sensitivity analyses to explore potential bias introduced by: the 
algorithm used to define CKD3-5; skin disease definitions; lack of accurate ethnicity 
data before 2006;32 information bias due to more frequent renal function testing 
among those taking medications requiring frequent blood testing; including non-
English CPRD practices; and missing BMI data (Appendix S5). 
We conducted secondary analyses: a) repeating the analyses after redefining 
individuals with atopic eczema as having mild, moderate or severe disease; and after 
redefining people with psoriasis as having mild/moderate or severe disease (based on 
recorded prescriptions for potent or systemic treatments, phototherapy record and 
referrals, Appendix S5; b) exploring potential effect modification by age and sex; and 
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c) using multinomial logistic regression to compare the relative risk of various levels 
of impaired kidney function among individuals with each skin condition to those 
without skin disease. To account for matching in the multinomial regression, we 
additionally adjusted for the matching variables (age group categorised as 45-64, 65-
69, 70-74, 75-79, 80-84, 85-89, 90+; and sex), and calculated 99% confidence 
intervals allowing for intra-group correlation within GP practices by using clustered 
robust standard errors. We estimated the population attributable risk (PAR), the 
proportion of CKD cases attributable to each skin condition, assuming causality: 
PAR=P(RR-1)/RR; where P is the proportion of CKD cases with the inflammatory 
skin condition, (using the calculated matched odds ratio as an estimate for the RR).48  
Cohort study  
For the cohort analysis of individuals with diabetes, we initially presented 
baseline characteristics of individuals with and without atopic eczema and psoriasis. 
We then calculated CKD3-5 incidence rates and used Poisson regression to estimate 
the rate ratio for CKD3-5 among those with and without atopic eczema and psoriasis, 
using the same framework of covariate selection described above. As in the case-
control study, we conducted sensitivity analyses to explore potential bias (Appendix 
S6). 
In all analyses, we used likelihood-ratio tests to calculate P-values (unless 
stated otherwise). We used 99% confidence intervals to reduce the risk of Type 1 
error in the context of multiple analyses.49 Statistical analysis was performed using 
Stata, version 15.1 IC (StataCorp LP, College Station, Texas). The study was 
approved by CPRD’s Independent Scientific Advisory Committee (#19_011), and the 
London School of Hygiene and Tropical Medicine Research Ethics Committee 
(#16353). 






We matched 56,602 adults with CKD3-5 in CPRD on 31/03/2018 with a 
control group of 268,305 people (Figure 1). Mean age (standard deviation [SD]) was 
78.6 years (10.4), and 42.3% (137,505) were men. Those with CKD3-5 were more 
likely to be obese than those without (38.8% versus 23.5%), and more likely to be 
current or ex-smokers (65.0% versus 59.6%). People with CKD3-5 were more likely 
to have a cardiovascular disease risk factor (i.e. smoking, hypertension, diabetes, 
obesity) or cardiovascular disease (Table 1). Characteristics by CKD3-5 category are 
provided in Appendix S5. 
We present the association between all four inflammatory skin disease and 
CKD3-5 in Table 2. Individuals with CKD3-5 were more likely to have a history of 
atopic eczema (odds ratio [OR] 1.14; 99% confidence interval [99%CI] 1.11 to 1.17), 
psoriasis (OR 1.13; 99%CI 1.08 to 1.19), or hidradenitis (OR 1.49; 99%CI 1.19 to 
1.85) than those without, after adjusting for age, sex, general practice and IMD, as 
well as diabetes, smoking, harmful alcohol use and obesity. CKD3-5 was associated 
with lower prevalence of rosacea (OR 0.92; 99%CI 0.87 to 0.97). After additionally 
adjusting for hypertension and cardiovascular morbidity (i.e. potential mediators), our 
results were slightly attenuated for all four skin diseases. (Table 2). Appendix S5 
includes absolute numbers and crude proportions of people with inflammatory skin 
diseases among those with and without CKD3-5.  
Participants with atopic eczema and psoriasis were more likely to have CKD3-
5 regardless of atopic eczema or psoriasis severity. The association was stronger in 
people with more severe skin disease (P[trend]<0.0001) (Figure 2, Appendix S5). In 
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stratified analyses, there was no evidence of a difference in the association between 
the inflammatory skin diseases and CKD3-5 between men and women, nor was there 
evidence for effect modification by age. Our multinomial regression results were 
consistent with the main regression analysis, but confidence intervals were wide. Our 
results were similar in sensitivity analyses (Appendix S5). Applying the calculated 
effect estimates, and assuming a causal association, 2.4% of CKD cases may be 
attributable to atopic eczema, 0.7% to psoriasis and 1.45% to hidradenitis 
(Supplement S5) 
Cohort study 
We identified 448,286 eligible individuals in CPRD between 01/04/2004 and 
31/3/2018 with a diabetes mellitus diagnosis. 335,827 remained after we excluded 
those who had at least one eGFR measurement <60 mL/min/1.73m2 or RRT before 
cohort entry. Mean age at cohort entry was 58.5 (SD 13.6) years, and 59.7% 
(200,372) were men. 9.4% (31,585) had atopic eczema, and 4.6% (15,476) had a 
psoriasis diagnosis (Appendix S6). There was no evidence for an association between 
pre-existing atopic eczema or psoriasis, and new-onset CKD3-5, a finding that did not 
differ in sensitivity analyses (Appendix S6). 
 
  





In our case-control study, people with CKD3-5 were more likely to have 
atopic eczema (14%), psoriasis (13%) and hidradenitis suppurativa (49%), compared 
to those without CKD3-5. There was no evidence to support that the link between 
inflammatory skin diseases and CKD3-5 was mediated through cardiovascular co-
morbidity or hypertension. A stronger association with CKD3-5 among those with 
severe atopic eczema and psoriasis was consistent with a dose-response association. 
However, those with rosacea were less likely to have CKS3-5, and we did not find an 
increased incidence of CKD3-5 among those with atopic eczema or psoriasis within a 
cohort of people with diabetes.    
Strengths and limitations 
We studied a large, nationally representative, population-based samples, 
assuring power and precision in assessing the link between inflammatory skin 
diseases and CKD3-5. Using real-world, routinely collected data, we were able to 
account for a wide range of potential confounders and mediators and conducted 
extensive sensitivity analyses. We explored four different conditions, following a 
rigorous, pre-approved protocol, and combined complementary approaches with 
different potential biases to ‘triangulate’ the association between inflammatory skin 
diseases and CKD3-5.50 Integrating diverse data, rather than concentrating on a single 
disease, supported our attempt to infer on inflammatory skin conditions in general. 
However, our study has several limitations. We regarded those without serum 
creatinine measurements as not having CKD3-5. As people will only have serum 
creatinine testing when it is indicated (i.e. in acute illness or incentivised monitoring 
in specific illnesses, e.g. diabetes) and early disease is often asymptomatic. We may 
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have misclassified people with undiagnosed silent CKD as being CKD-free, 
potentially diluting our effect estimates towards null. However, a previous validation 
study has shown that the approach we took reliably captures prevalent CKD3-5 in 
CPRD.25 Additionally, due to infrequent urinary testing, we were unable to capture 
albuminuria, which may have been a more sensitive marker of inflammatory kidney 
damage. Skin manifestations of late-stage CKD could have been misclassified as 
inflammatory skin diseases (e.g. xerosis). This limitation of the case-control design 
was mitigated by our use of validated algorithms (where available) to reduce the 
likelihood of misclassifying skin disease. Finally, we were unable to capture 
potentially relevant covariates, including environmental and genetic risk factors, in 
routinely collected data. Of note, we were not able to capture information on the use 
of biologic medications, which may have had a mediating role in the development of 
CKD among people with severe skin conditions. 
Comparisons to the existing literature 
Longitudinal studies have demonstrated increased CKD incidence in people 
with psoriasis.11–14 Cross-sectional or smaller-scale evidence previously suggested an 
association between CKD and hidradenitis suppurativa,15 and rosacea.16 There have 
been reports of nephrotic syndrome and Henoch-Schonlein purpura in children with 
atopy;51–54 and Danish analysis suggests that mortality due to urogenital diseases 
(ICD10 code groups N00-N99) is more common among those with eczema, although 
absolute numbers were small.17 Our findings are consistent with these previous 
reports, but to the best of our knowledge, the association between atopic eczema and 
CKD has not been previously explored. Unlike a previous smaller Taiwanese cohort 
study,16 we did not demonstrate an association between rosacea and CKD3-5. While 
GP diagnoses are highly concordant with those made by specialists,55 a previous 
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report also suggested substantial misclassification of rosacea by GPs, especially with 
acne and seborrhoeic dermatitis.42 Misclassified rosacea diagnoses are likely to be 
non-differential (i.e. to occur regardless of CKD status), and may have therefore 
diluted the observed associated between rosacea and CKD3-5 towards null.  
Interpretation, implications, future research 
 We explored a link between inflammatory skin diseases and CKD. We were 
able to include a large sample of people with atopic eczema and psoriasis, but 
relatively few with hidradenitis suppuritiva and rosacea, Our case-control analysis 
supported a positive association between atopic eczema, psoriasis and hidradenitis 
suppuritiva and CKD, but a negative association between rosacea and CKD. A cohort 
analysis of people with diabetes failed to demonstrate the associations of atopic 
eczema and psoriasis with CKD3-5. We discuss below potential explanations for our 
findings, as well as for the discrepancy between the results of the complementary 
designs.  
We cannot ascertain the temporal direction using our prevalent case-control 
design (due to its cross-sectional nature), but the consistent results across multiple 
skin conditions and the apparent association between increasing atopic eczema and 
psoriasis severity and increasing CKD3-5 highlight the need for further research to 
explore a causal link. The underlying mechanism for a potential link between 
inflammatory skin conditions and CKD remains unknown, but one compelling 
explanation involves chronic inflammation.56 Autoimmune inflammation is mediated 
through abnormal activation of the innate immune system, which plays an important 
role in common skin diseases, such as psoriasis, atopic eczema, hidradenitis 
suppurativa and rosacea.57–60 Circulating reactive oxygen species and inflammatory 
cytokines (resulting from the inflammatory process) could impair endothelial function 
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leading to accelerated atherosclerosis (with consequent kidney vasculature damage) or 
independently modulate kidney damage.61 However, we observed little change in our 
results after accounting for potential mediators (i.e. ischemic heart disease, chronic 
heart failure and peripheral arterial disease) and in sensitivity analyses. Our findings, 
therefore, do not support a mediating role of metabolic syndrome, cardiovascular 
morbidity, hypertension or nephrotoxic medications in the development of CKD 
among people with inflammatory skin conditions. We were unable to account for the 
use of biologic medications, which may have mediated the association among those 
with moderate to severe skin conditions; further research is needed to elucidate the 
role of this medication group.  While the results of the cohort study did not mirror 
those of our main case-control design, we believe they highlight methodological 
issues for future research but do not invalidate its results.  
In our cohort study of people with diabetes, there was no evidence for an 
increased CKD3-5 incidence among people with atopic eczema or psoriasis. 
However, the mean follow-up for participants in the cohort was 5.3 years, which may 
have been insufficient to capture differences in CKD3-5 onset between those with and 
without skin disease. We chose to follow people with diabetes to assure reliable 
capture of incident CKD, but this approach may have inadvertently precluded us from 
observing an association. Diabetes, together with hypertension, is associated with 
most cases of CKD.62 We, therefore, speculate that the high baseline risk for 
developing CKD3-5 in a cohort of people with diabetes may obscure a much smaller 
contributing effect of an inflammatory skin condition.  
There is no firm evidence to support routine population screening for 
CKD,38,63 but some stakeholders advocate targeted testing of individuals at high-
risk.7,64 If non-communicable inflammatory skin conditions are indeed risk-factors or 
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markers for CKD, future guidelines may consider affected individuals as at-risk 
populations for regular renal function monitoring.  
Conclusion 
We found that atopic eczema, psoriasis, and hidradenitis suppurativa were weakly 
associated with CKD, independent of obesity, cardiovascular morbidity, or non-
biologic nephrotoxic skin medications. We did not find evidence supporting this 
association in a cohort of people with diabetes. Further research is needed to elucidate 
the nature and temporal direction of this link, to account for other potential 
confounders, and explore whether targeted screening for CKD in people with 
inflammatory skin diseases is justified.  
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Figure 1 – Case-control study: flowchart illustrating selection of the study population. 
Abbreviations: CKD, chronic kidney disease; CPRD, Clinical Practice Research Datalink; 
eGFR, estimated glomerular filtration rate;   
* Recorded creatinine values were multiplied by 0.95 to give a conservative estimate, 
corrected for lack of test standardisation. [1,2] 
CKD on index date was defined if two consecutive eGFR measurements (including the one 
closest to the index date) were below 60 ml/min/1.73m2 and at least 90 days apart; or if there 
were diagnostic codes indicating renal replacement therapy or a kidney transplant.  
People alive and registered for at least 12 
months in an “up-to-standard” practice  on 
March 31st 2018
N=2,183,595
Eligible at index date
N=1,600,508












CKD cases for main analysis 
(eGFR<60 ml/min/1.73m2, corrected*)
N=57,618
eligible for 1:5 matching on age, sex and 
GP-practice
CKD cases for sensitivity analysis 
(eGFR<45 ml/min/1.73m2)
N=19,906
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Figure 2. Case-control study: Odds ratios (99% CI) for prevalent CKD3-5 among individuals 
with atopic eczema (a) and psoriasis (b), by the severity of the skin condition. 
 
 
Abbreviations: CKD3-5, chronic kidney disease stages 3-5 
Odds ratios are derived from conditional logistic regression models, stratified on the matching 
variables (i.e. age, sex and GP-practice), and presented with 99% confidence intervals. All P-
values for trend <0.0001 
The minimally adjusted model is adjusted for age, sex, general practice and index of multiple 
deprivation (IMD);  the fully adjusted model additionally accounts for diabetes status, 
smoking, harmful alcohol use and obesity; a final model, additionally adjusted for 
hypertension and cardiovascular disease (ischemic heart disease, chronic heart failure and 
peripheral arterial disease) as potential mediators. 
* Compared to those without the skin condition. 
 
  




Table 1. Case-control study: Characteristics of the study population. 
 CKD3-5 No CKD3-5 
 N=56,602 N=268,305 
Age, years, mean (SD) 79.1 (10.6) 78.4 (10.4) 
   25-64 4,782 (8.4%) 23,910 (8.9%) 
   65-74 10,484 (18.5%) 52,401 (19.5%) 
   75-84 22,549 (39.8%) 111,696 (41.6%) 
   85+ 18,787 (33.2%) 80,298 (29.9%) 
Sex, male 24,039 (42.5%) 113,466 (42.3%) 
IMD   
   1 lowest quintile 13,288 (23.5%) 65,167 (24.3%) 
   2 9,151 (16.2%) 44,189 (16.5%) 
   3 12,071 (21.3%) 57,086 (21.3%) 
   4 12,581 (22.2%) 58,031 (21.6%) 
   5 highest quintile 9,511 (16.8%) 43,832 (16.3%) 
Ethnicity*   
   White 26,237 (94.9%) 117,606 (94.9%) 
   South Asian 742 (2.7%) 2,941 (2.4%) 
   Black 354 (1.3%) 1,869 (1.5%) 
   Other/Mixed 310 (1.1%) 1,564 (1.3%) 
Body Mass Index (BMI)*, kg/m2 , mean (SD) 28.4 (5.8) 26.9 (5.2) 
   Underweight (<18.5) 748 (1.7%) 5,429 (2.8%) 
   Normal (20.0-24.0) 11,443 (26.6%) 67,144 (35.1%) 
   Overweight (25.0-29.0) 16,260 (37.8%) 73,763 (38.6%) 
   Obese (>30.0) 14,555 (33.8%) 44,923 (23.5%) 
Current/former smoker * 36,741 (65.0%) 153,407 (59.6%) 
Hypertension 44,777 (79.1%) 147,648 (55.0%) 
Ischemic heart disease 13,209 (23.3%) 37,399 (13.9%) 
Peripheral arterial disease 3,495 (6.2%) 7,971 (3.0%) 
Heart failure 7,820 (13.8%) 12,173 (4.5%) 
Diabetes 16,612 (29.3%) 36,819 (13.7%) 
Harmful alcohol use 2,789 (4.9%) 14,577 (5.4%) 
Methotrexate** 1,184 (2.1%) 4,332 (1.6%) 
Ciclosporin** 428 (0.8%) 206 (0.1%) 
Mycophenolate mofetil** 906 (1.6%) 206 (0.1%) 
Renal function, mL/min/1.73m2    
   eGFR 45-59 (3a) 32,895 (58.1%) N/A 
   eGFR 30-44 (3b) 17,418 (30.8%) N/A 
   eGFR <30 (4/5) 5,601 (9.9%) N/A 
   RRT/renal transplant 688 (1.2%) N/A 
Abbreviations: CKD3-5, chronic kidney disease stages 3-5; eGFR, estimated glomerular 
filtration rate; IMD, index of multiple deprivation; IQR, interquartile range RRT, renal 
replacement therapy; SD, standard deviation;  
* Missing values: ethnicity, N=173,284; BMI, N=90,672; smoking status, N=11,281 
** Record of at least one previous prescription 
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Table 2. Case-control study: Odds ratios (99% CI) for prevalent CKD3-5 among individuals 
with inflammatory skin diseases. 
 
Model 1 - minimally 
adjusted 
Model 2 -  
fully adjusted 
Model 3 - additionally 
adjusted for potential 
mediators 
 N=324,907 N=228,812 N=228,812 
Atopic eczema 1.24 (1.21-1.27) 1.14 (1.11-1.17) 1.1 (1.07-1.13) 
Psoriasis 1.24 (1.19-1.29) 1.13 (1.08-1.19) 1.12 (1.07-1.17) 
Hidradenitis 
suppuritiva 1.62 (1.34-1.97) 1.49 (1.19-1.85) 1.45 (1.16-1.82) 
Rosacea 0.96 (0.91-1) 0.92 (0.87-0.97) 0.91 (0.86-0.96) 
 
Odds ratios are derived from conditional logistic regression models, stratified on the matching 
variables (i.e. age, sex and GP-practice), and presented with 99% confidence intervals 
The minimally adjusted model is adjusted for age, sex, general practice and index of multiple 
deprivation (IMD);  the fully adjusted model additionally accounts for diabetes status, 
smoking, harmful alcohol use and obesity; a final model, additionally adjusted for 
hypertension and cardiovascular disease (ischemic heart disease, chronic heart failure and 
peripheral arterial disease) as potential mediators. 
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